These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Expression of bcl-2 and bax protein in uterine leiomyosarcomas and leiomyomas].
    Author: Zhang ZL, Zhang Y, Zhou JH.
    Journal: Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2005 Apr; 30(2):183-6. PubMed ID: 15898430.
    Abstract:
    OBJECTIVE: To determine the expression and significance of the apoptosis regulatory protein bcl-2 and bax in uterine leiomyosarcomas and uterine leiomyomas. METHODS: The expression of bcl-2 and bax were examined by immunohistochemical ABC staining with specific antibodies in 34 cases of uterine leiomyosarcomas (18 cases in stage I , 1 in stage II , 8 in stage III, and 7 in stage IV ), 34 uterine leiomyomas and 34 normal myometrium samples. RESULTS: Bcl-2 expression was higher in uterine leiomyomas than that in normal myometrium and in uterine leiomyosarcoma (P < 0.01 ); bcl-2 expression in uterine leiomyosarcoma was higher than that in normal myometrium (P < 0.05). Bax expression in normal myometrium was higher than that in leiomyomas and in uterine leiomyosarcoma (P < 0.01). There was no obvious difference in bax expression between leiomyomas and leiomyosarcoma (P > 0.05). Both the expressions of bcl-2 and bax proteins in stage I - II were higher than those of in stage III - IV (P < 0.01). The bcl-2 positive leiomyosarcoma has a favorable clinical outcome than that of bcl-2 negative. CONCLUSION: The imbalance between the expression of bcl-2 and bax may play a certain role in the genesis of the uterine leiomyomas and leiomyosarcomas. Bcl-2 and bax may be involved in the early stage of the tumor genesis of uterine leiomyosarcoma. Bcl-2 might correlate with the prognosis of the uterine leiomyosarcoma.
    [Abstract] [Full Text] [Related] [New Search]